PPT-Evolving Therapies for Elderly Patients with Blood Cancers

Andrew Artz MD MS Associate Professor of Medicine Clinical Director Hematopoietic Cellular Therapy Program Background New diagnostic tools New Drugs Blood and Marrow Transplant 2 Presentation Title Here . YELLOW MASS. IS A TUMOR. Answer the following questions independently. . If you don’t know the answer, make the best possible educated guess you can. . Do not leave any questions unanswered.. What causes cancer?. Giorgio V. Scagliotti. University. of . Torino,. . Department. . of . Oncology. giorgio.scagliotti@unito.it. Key. . points. of the . presentation. Incidence. Age . cut. -off. Comorbidity. & . Farhad. . Ravandi. , . MD. Professor of Medicine. University of Texas MD Anderson Cancer Center. Disclosure of Conflicts of Interest. Dr. . Ravandi. discloses that he is a consultant/advisor for Pfizer, . Medical Director, Heart Failure and Cardiac Transplant Program. University of Pennsylvania. What Are Advanced Therapies?. Heart Transplant. Ventricular Assisted Devices (VAD). Mechanical Circulatory Support (MCS). ACCF/AHA 2011. Expert Consensus Document. . . Developed in collaboration with the American Academy of Neurology, Association of Black Cardiologists, American Geriatrics Society, American Society of Hypertension, American Society of Nephrology, American Society for Preventive Cardiology, and the European Society of Hypertension. of . Age. . Hiromichi. Suzuki, Tsutomu . Inoue,Tomohiro. . Kikuta. , . Yusuke Watanabe, Hirokazu Okada.  . . Department of Nephrology, Saitama Medical University. Nephro-2014. COI. 　. Author. yo. Patient). A 88 . yo. man with hypertension, COPD, . atrial. fibrillation presents with severe CP and is diagnosed with a NSTEMI. He is found to have 90% LAD occlusion and receives a drug eluting stent. Current meds: . Andrew Artz, MD, MS. Associate Professor of Medicine. Clinical Director, Hematopoietic Cellular Therapy Program. Background. New diagnostic tools. New Drugs . Blood and Marrow Transplant. 2. Presentation Title Here |. 1. Avoidable deaths from childhood cancers in LMICs result from lack of diagnosis, misdiagnosis or delayed diagnosis, obstacles to accessing care, abandonment of treatment, death from toxicity, and higher rates of relapse. Hence ascertaining the clinic-pathological profile of childhood cancers is essential for allocation and management of resources.. Dr . Natalie Cook. Senior Clinical Lecturer in Experimental Cancer Medicine, University of Manchester. Honorary Consultant in Medical Oncology. Christie NHS Foundation Trust. Talk overview. Liquid biopsy technologies . May 25, 2013. Mala Joneja, MD MEd FRCPC . Identify factors that contribute to risk in the medical treatment of Rheumatic Diseases in the elderly population. Identify risks associated with specific pharmacological interventions in the elderly. 41 Patients Erdoan Özgür 1 , Uur Kamilolu 2 , Peyker Temiz 3 , Görkem Eskiizmir 2 1 Department of Otorhinolaryngology, Mula Stk Koçman University School of Medicine, What is cancer?. Definition. a term used for diseases in which . abnormal cells divide without control . and are able to . invade other tissues. Cancer cells spread to other parts of the body through the . Summary deck. 2. With over 7,000 medicines in development, the exciting new wave of medical innovation will play a key role in . addressing the challenges faced by patients and healthcare systems . Source: Health Advances analysis; Adis R&D Insight Database. March 2015, compiled by PhRMA.